Abstract
BackgroundCombination therapy with an inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) is recommended for patients with asthma symptomatic on ICS alone. However, there is ongoing debate regarding the risk-benefit...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have